5:43 PM
 | 
Apr 29, 2014
 |  BC Extra  |  Top Story

BMS acquires iPierian, reports 1Q14 earnings

Bristol-Myers Squibb Co. (NYSE:BMY) reported mixed 1Q14 financial results on Tuesday and separately said it acquired neurology play iPierian Inc. (South San Francisco, Calif.) for $175 million in cash up front and up to $550 million in milestones, plus royalties. iPierian's IPN007 is a preclinical humanized mAb targeting microtubule-associated protein tau...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >